Amring gains global rights to LYSTEDA
3 December 2020 -

Generic pharmaceutical company Amring Pharmaceuticals Inc has agreed to acquire the global rights to LYSTEDA (tranexamic acid) from Ferring International Center SA, the company announced on Wednesday.

LYSTEDA is a first-in-class, non-hormonal therapy indicated for the treatment of women with cyclic heavy menstrual bleeding.

Amring has been marketing the authorised generic version of LYSTEDA in the United States since 14 March 2016.

This deal further secures Amring's position as a market leader in the treatment of heavy menstrual bleeding and expands product opportunities in markets outside of the US, according to Daniel Carbery, president and CEO of Amring.